RARE · Ultragenyx Pharmaceutical Inc.
Market Cap
$1.42B
Shares
98.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$14.30
Open$14.43
Day$14.13–14.70
52W close$14.30–36.54
Avg vol 30d3.7M
Short int17.1M · 17.4% float · 8.0d
Short vol44%
Last earningsAug 4, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 7 wks
filed Aug 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$717.00M
Trailing 12 months
Net income (TTM)
−$586.00M
Trailing 12 months
Revenue growth YoY
+28.1%
Year over year
Operating margin
-73.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-34.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.5%
Year over year · more shares
Price change (1Y)
-54.0%
Trailing year
Short interest
17.4%
Latest settlement · 8.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−44%
below
Price vs 50-day avg
−46%
below
RSI (14)
20
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−46%
trailing
6-month return
−28%
trailing
YTD return
−38%
this year
Relative strength
−46%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $26 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +62 funds added
Insider flow
Distributing
Net -$52.4K over 90 days · 100% sells
Short interest
Rising
17.39% of float · ▲ +7.9% MoM · 8.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
317 holders — near 3-yr high, broad support
Squeeze score
61
elevated · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
EPS growth
+7%
Y/Y
Free cash flow
$-472.0M
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−61%
past year
ATR
11.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Total revenue
· full year 2026
Initiated
$730M – $760M
prior FY $673M
midpoint +10.7% Y/Y
Crysvita revenue
· full year 2026
Initiated
$500M – $520M
Dojolvi revenue
· full year 2026
Initiated
$100M – $110M
Prior guidance
period ended
· from the Earnings Call filed Nov 2, 2021
Crysvita revenue in Ultragenyx territories
· 2021
$180M – $190M
Guided vs delivered
· last 1 settled
Revenue in Ultragenyx territories
2021
guided $180M – $190M
$351.41M
Beat +89.9%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−44%
Bearish
Price vs 50-day avg
−46%
Bearish
RSI (14)
20
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $26 › 200d $26 — 50d above 200d
Institutional flow
Accumulating
+6% holders QoQ · +62 funds added
Insider flow
Distributing
Net -$52.4K over 90 days · 100% sells
Short interest
Rising
17.39% of float · ▲ +7.9% MoM · 8.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
317 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $14
Now $14 · 0%
Range high $37
vs 200-day avg -44%
vs 50-day avg -46%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RARE
this stock
Ultragenyx Pharmaceutical Inc.
|
$1.42B | -37.8% | +20.2% | — | 17.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.40B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.67B | +1.2% | +20.8% | 19.6 | 2.5% |
|
ARGX
Argenx SE
|
$61.60B | +17.1% | — | — | 2.0% |
|
CSLLY
Csl Ltd
|
$57.41B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RARE | -3.7% | -45.8% | -28.0% | -43.3% | -37.8% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -2.6% | -44.0% | -45.9% | -42.9% | -49.9% |
Key facts
CIK
1515673
CUSIP
90400D108
13F (30d)
165 filings
164 filers
Visit website
Investor relations